Trials and tribulations of skin iontophoresis in therapeutics

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 63-71

  Roustit, Matthieu ^a,b   Blaise, Sophie ^a,c   Cracowski, Jean Luc ^a,b  

^a University Grenoble Alpes   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Iontophoresis; skin; topical drug administration

Indexed keywords

ACICLOVIR; ADRENALIN PLUS LIDOCAINE; ALMOTRIPTAN; AZELAIC ACID; BOSENTAN; BOTULINUM TOXIN A; CALCITONIN; CORTICOSTEROID; DEXAMETHASONE; EMLA; FENTANYL; GONADORELIN; ILOPROST; LIDOCAINE; MORPHINE; NICOTINE; PHENOBARBITAL; PROSTAGLANDIN DERIVATIVE; RANITIDINE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TERBINAFINE; TREPROSTINIL; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN; ZELRIX; ZOLMITRIPTAN; ANALGESIC AGENT; DRUG; LOCAL ANESTHETIC AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

APPLICATION SITE ERYTHEMA; ARTICLE; CARPAL TUNNEL SYNDROME; CHEST TIGHTNESS; CHLOASMA; DRUG DELIVERY SYSTEM; DRY EYE; EDEMA; ELECTRIC CURRENT; FATIGUE; FINGER ULCER; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPOTENSION; IONTOPHORESIS; IONTOPHORETIC DELIVERY DEVICE; JUVENILE RHEUMATOID ARTHRITIS; MALAISE; MEDICAL DEVICE; MICRODIALYSIS; MIGRAINE; NON INVASIVE PROCEDURE; NONHUMAN; ONYCHOMYCOSIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; SCLERODERMA; SEDATION; SIDE EFFECT; SKIN DISCOMFORT; SKIN IONTOPHORESIS; SKIN IRRITATION; SKIN SENSATION; SKIN TINGLING; SKIN ULCER; STRATUM CORNEUM; TACHYCARDIA; URTICARIA; ADVERSE EFFECTS; BIOLOGICAL MODEL; COMPLICATION; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES; SCLERODERMA, LOCALIZED; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANALGESICS; ANESTHETICS, LOCAL; DRUG DELIVERY SYSTEMS; HUMANS; IONTOPHORESIS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SCLERODERMA, LOCALIZED; SKIN ABSORPTION; SKIN ULCER; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84891060507     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12128     Document Type: Article

References (72)

1. Costello CT, Jeske AH,. Iontophoresis: applications in transdermal medication delivery. Phys Ther 1995; 75: 554-563.
2. Helmstadter A,. The history of electrically-assisted transdermal drug delivery ('iontophoresis'). Pharmazie 2001; 56: 583-587.
3. Leduc S,. Ionisation destructive. Ses indications, ses résultats immédiats ou éloignés. In: Iiie Congrès International De Physiothérapie (20 Mars-2 Avril 1910). Paris: Masson & Cie, 1910; 164-174.
4. Kasha PC, Banga AK,. A review of patent literature for iontophoretic delivery and devices. Recent Pat Drug Deliv Formul 2008; 2: 41-50.
5. Kalia YN, Naik A, Garrison J, Guy RH,. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-658.
6. Leboulanger B, Guy RH, Delgado-Charro MB,. Reverse iontophoresis for non-invasive transdermal monitoring. Physiol Meas 2004; 25: R35-50.
7. Blaise S, Roustit M, Hellmann M, Millet C, Cracowski JL,. Cathodal Iontophoresis of Treprostinil Induces a Sustained Increase in Cutaneous Blood Flux in Healthy Volunteers. J Clin Pharmacol 2013; 53: 58-66.
8. Dixit N, Bali V, Baboota S, Ahuja A, Ali J,. Iontophoresis-an approach for controlled drug delivery: a review. Curr Drug Deliv 2007; 4: 1-10.
9. Gratieri T, Kalaria D, Kalia YN,. Non-invasive iontophoretic delivery of peptides and proteins across the skin. Expert Opin Drug Deliv 2011; 8: 645-663.
10. Artusi M, Nicoli S, Colombo P, Bettini R, Sacchi A, Santi P,. Effect of chemical enhancers and iontophoresis on thiocolchicoside permeation across rabbit and human skin in vitro. J Pharm Sci 2004; 93: 2431-2438.
11. Roustit M, Blaise S, Cracowski JL,. Sodium nitroprusside iontophoresis on the finger pad does not consistently increase skin blood flow in healthy controls and patients with systemic sclerosis. Microvasc Res 2009; 77: 260-264.
12. Siddoju S, Sachdeva V, Friden PM, Yu YY, Banga AK,. Acyclovir skin depot characterization following in vivo iontophoretic delivery. Skin Res Technol 2011; 17: 234-244.
13. Takasuga S, Yamamoto R, Mafune S, Sutoh C, Kominami K, Yoshida Y, Ito M, Kinoshita M,. In-vitro and in-vivo transdermal iontophoretic delivery of tramadol, a centrally acting analgesic. J Pharm Pharmacol 2011; 63: 1437-1445.
14. Calatayud-Pascual MA, Balaguer-Fernandez C, Serna-Jimenez CE, Del Rio-Sancho S, Femenia-Font A, Merino V, Lopez-Castellano A,. Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011; 416: 189-194.
15. Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Preat V, Guy RH,. In vivo methods for the assessment of topical drug bioavailability. Pharm Res 2008; 25: 87-103.
16. Benson H, Watkinson A,. Topical and Transdermal Drug Delivery: Principles and Practice. Hoboken, NJ: John Wiley & Sons, 2012.
17. Rougier A, Dupuis D, Lotte C, Roguet R, Schaefer H,. In vivo correlation between stratum corneum reservoir function and percutaneous absorption. J Invest Dermatol 1983; 81: 275-278.
18. Kreilgaard M,. Assessment of cutaneous drug delivery using microdialysis. Adv Drug Deliv Rev 2002; 54: (Suppl. 1): S99-121.
19. Holmgaard R, Nielsen JB, Benfeldt E,. Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: current state and future perspectives. Skin Pharmacol Physiol 2010; 23: 225-243.
20. Au WL, Skinner MF, Benfeldt E, Verbeeck RK, Kanfer I,. Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Skin Pharmacol Physiol 2012; 25: 17-24.
21. Brunner M, Davies D, Martin W, Leuratti C, Lackner E, Muller M,. A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects. Br J Clin Pharmacol 2011; 71: 852-859.
22. Tegeder I, Muth-Selbach U, Lotsch J, Rusing G, Oelkers R, Brune K, Meller S, Kelm GR, Sorgel F, Geisslinger G,. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther 1999; 65: 357-368.
23. Stagni G, O'Donnell D, Liu YJ, Kellogg DL, Morgan T, Shepherd AM,. Intradermal microdialysis: kinetics of iontophoretically delivered propranolol in forearm dermis. J Control Release 2000; 63: 331-339.
24. Turner J, Belch JJ, Khan F,. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med 2008; 18: 109-116.
25. Roustit M, Cracowski JL,. Non-invasive assessment of skin microvascular function in humans: an insight into methods. Microcirculation 2012; 19: 47-64.
26. Eisenach JH, Atkinson JL, Fealey RD,. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc 2005; 80: 657-666.
27. Zhao M, Song B, Pu J, Wada T, Reid B, Tai G, Wang F, Guo A, Walczysko P, Gu Y, Sasaki T, Suzuki A, Forrester JV, Bourne HR, Devreotes PN, McCaig CD, Penninger JM,. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature 2006; 442: 457-460.
28. Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A,. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg 2004; 98: 427-433. table of contents.
29. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S,. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 2004; 291: 1333-1341.
30. Viscusi ER, Siccardi M, Damaraju CV, Hewitt DJ, Kershaw P,. The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth Analg 2007; 105: 1428-1436. table of contents.
31. Siegel SJ, O'Neill C, Dube LM, Kaldeway P, Morris R, Jackson D, Sebree T,. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 2007; 24: 1919-1926.
32. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T,. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009; 49: 817-825.
33. Rapoport AM, Freitag F, Pearlman SH,. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010; 24: 929-940.
34. NuPathe. NuPathe's Zecuity approved by the FDA for the acute treatment of migraine. Available at http://ir.nupathe.com/press-releases/nupathe-s-zecuity- approved-by-the-fda-for-the-acut-nasdaq-path-975802 (last accessed 25 April 2013).
35. Patel SR, Zhong H, Sharma A, Kalia YN,. Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur J Pharm Biopharm 2009; 72: 304-309.
36. Escobar-Chavez JJ, Merino V, Lopez-Cervantes M, Rodriguez-Cruz IM, Quintanar-Guerrero D, Ganem-Quintanar A,. The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation. Curr Drug Discov Technol 2009; 6: 171-185.
37. Djabri A, Guy RH, Delgado-Charro MB,. Transdermal iontophoresis of ranitidine: an opportunity in paediatric drug therapy. Int J Pharm 2012; 435: 27-32.
38. Djabri A, Guy RH, Delgado-Charro MB,. Passive and iontophoretic transdermal delivery of phenobarbital: implications in paediatric therapy. Int J Pharm 2012; 435: 76-82.
39. Chen H, Zhu H, Zheng J, Mou D, Wan J, Zhang J, Shi T, Zhao Y, Xu H, Yang X,. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 2009; 139: 63-72.
40. Riviere JE, Monteiro-Riviere NA, Inman AO,. Determination of lidocaine concentrations in skin after transdermal iontophoresis: effects of vasoactive drugs. Pharm Res 1992; 9: 211-214.
41. Wakita R, Oono Y, Oogami S, Hayashi S, Umino M,. The relation between epinephrine concentration and the anesthetic effect of lidocaine iontophoresis. Pain Pract 2009; 9: 115-121.
42. Lidosite®. Full Prescribing Information. Vyteris Inc. 2004.
43. Galinkin JL, Rose JB, Harris K, Watcha MF,. Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children. Anesth Analg 2002; 94: 1484-1488. table of contents.
44. Zempsky WT, Sullivan J, Paulson DM, Hoath SB,. Evaluation of a low-dose lidocaine iontophoresis system for topical anesthesia in adults and children: a randomized, controlled trial. Clin Ther 2004; 26: 1110-1119.
45. Holovics HJ, Anderson CR, Levine BS, Hui HW, Lunte CE,. Investigation of drug delivery by iontophoresis in a surgical wound utilizing microdialysis. Pharm Res 2008; 25: 1762-1770.
46. Kearns GL, Heacook J, Daly SJ, Singh H, Alander SW, Qu S,. Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability. Pediatrics 2003; 112: 578-582.
47. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A, Friden PM, Murthy SN,. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009; 98: 4130-4140.
48. Amichai B, Nitzan B, Mosckovitz R, Shemer A,. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2010; 162: 46-50.
49. Morrel EM, Spruance SL, Goldberg DI,. Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. Clin Infect Dis 2006; 43: 460-467.
50. Kalluri H, Banga AK,. Transdermal delivery of proteins. AAPS PharmSciTech 2011; 12: 431-441.
51. Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd,. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011; 5: 633-643.
52. Mina R, Melson P, Powell S, Rao M, Hinze C, Passo M, Graham TB, Brunner HI,. Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 1511-1516.
53. Amirjani N, Ashworth NL, Watt MJ, Gordon T, Chan KM,. Corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial. Muscle Nerve 2009; 39: 627-633.
54. Kavanagh GM, Oh C, Shams K,. BOTOX delivery by iontophoresis. Br J Dermatol 2004; 151: 1093-1095.
55. Kavanagh GM, Shams K,. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. J Am Acad Dermatol 2006; 55: S115-117.
56. Montaser-Kouhsari L, Zartab H, Fanian F, Noorian N, Sadr B, Nassiri-Kashani M, Firooz A,. Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat 2013. doi: 10.3109/09546634.2012.739679.
57. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP,. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407-1414.
58. Murray AK, Herrick AL, Gorodkin RE, Moore TL, King TA,. Possible therapeutic use of vasodilator iontophoresis. Microvasc Res 2005; 69: 89-94.
59. Murray AK, Moore TL, King TA, Herrick AL,. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis? Rheumatology (Oxford) 2008; 47: 76-79.
60. Blaise S, Roustit M, Millet C, Ribuot C, Boutonnat J, Cracowski JL,. Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats. Br J Pharmacol 2011; 162: 557-565.
61. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C,. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-3993.
62. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR,. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-38.
63. Roustit M, Blaise S, Arnaud C, Hellmann M, Millet C, Godin-Ribuot D, Dufournet B, Boutonnat J, Ribuot C, Cracowski JL,. Iontophoresis of endothelin receptor antagonists in rats and men. PLoS ONE 2012; 7: e40792.
64. Li GL, Van Steeg TJ, Putter H, Van Der Spek J, Pavel S, Danhof M, Bouwstra JA,. Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial. Br J Dermatol 2005; 153: 404-412.
65. ECRI Institute. Lesions and shocks during iontophoresis. Health Devices 1997; 26: 123-125.
66. Meffert JJ,. Galvanic urticaria. Cutis 1999; 63: 327-328.
67. Lacy KE, Kennedy CT,. Galvanic urticaria. Clin Exp Dermatol 2006; 31: 739-740.
68. Warden GD,. Electrical safety in iontophoresis. Rehab Manag 2007; 20: 22-23.
69. Prescrire. Fentanyl transdermal system: market withdrawal. Exposes patients to a risk of overdose. The market withdrawal, due to a manufacturing defect, is more than welcome. Prescrire Int 2009; 18: 110.
70. European Medicines Agency. Ionsys (fentanyl)-Non-renewal of the marketing authorisation in the European Union, 2011. Available at http://www.ema.europa. eu/docs/en-GB/document-library/Public-statement/2011/01/WC500101495.pdf (last accessed 27 March 2012).
71. Pershad J, Steinberg SC, Waters TM,. Cost-effectiveness analysis of anesthetic agents during peripheral intravenous cannulation in the pediatric emergency department. Arch Pediatr Adolesc Med 2008; 162: 952-961.
72. Viscusi ER, Schechter LN,. Patient-controlled analgesia: finding a balance between cost and comfort. Am J Health Syst Pharm 2006; 63: S3-13. quiz S15-6.